CommentaryManagement of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
Cited by (0)
Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories, Pfizer, and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn’s and Colitis Foundation, Broad Medical Research Program, Abbvie, Janssen, Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda.